Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNG-6132
- Development stage
- Preclinical
- Lead developer
- Tango Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TNG-6132 (also known as TNG0746132) is a potent, selective, reversible, and orally bioavailable small molecule allosteric inhibitor of ubiquitin-specific peptidase 1 (USP1). Developed by Tango Therapeutics, TNG-6132 binds to a cryptic allosteric pocket in the USP1-UAF1 complex, preventing the deubiquitination of substrates such as monoubiquitinated proliferating cell nuclear antigen (Ub-PCNA) and Ub-FANCD2. This inhibition leads to replication fork instability, accumulation of single-stranded DNA (ssDNA) gaps, and DNA damage. TNG-6132 is utilized preclinically to demonstrate synthetic lethality in BRCA1/2-deficient and homologous recombination deficient (HRD+) cancer models, and has shown efficacy in overcoming PARP inhibitor resistance in ovarian and breast cancer models.
- Other names
- Compound 18Compound18Compound-18
02
Targets
USP1 (Ubiquitin-specific protease 1)UAF1 (WD repeat-containing protein 48)
Beyond the preview
Go deeper on TNG-6132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNG-6132.